Prelude Capital Management’s Intersect ENT, Inc XENT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-197,047
| Closed | -$5.52M | – | 2266 |
|
|
2022
Q1 | $5.52M | Buy |
197,047
+161,258
| +451% | +$4.42M | 0.16% | 108 |
|
|
2021
Q4 | $977K | Buy |
35,789
+8,362
| +30% | +$227K | 0.03% | 634 |
|
|
2021
Q3 | $746K | Buy |
+27,427
| New | +$678K | 0.02% | 696 |
|
|
2020
Q1 | – | Sell |
-279
| Closed | -$7K | – | 2224 |
|
|
2019
Q4 | $7K | Buy |
279
+9
| +3% | +$182 | ﹤0.01% | 1747 |
|
|
2019
Q3 | $5K | Buy |
+270
| New | +$4.92K | ﹤0.01% | 1570 |
|
|
2019
Q2 | – | Sell |
-126
| Closed | -$3.4K | – | 2280 |
|
|
2019
Q1 | $4K | Buy |
+126
| New | +$3.9K | ﹤0.01% | 1662 |
|
|
2018
Q3 | – | Sell |
-15,011
| Closed | -$562K | – | 2146 |
|
|
2018
Q2 | $562K | Sell |
15,011
-5,528
| -27% | -$217K | 0.04% | 501 |
|
|
2018
Q1 | $807K | Buy |
20,539
+16,412
| +398% | +$600K | 0.06% | 330 |
|
|
2017
Q4 | $134K | Sell |
4,127
-6,750
| -62% | -$202K | 0.01% | 718 |
|
|
2017
Q3 | $339K | Buy |
+10,877
| New | +$322K | 0.03% | 484 |
|
|
2017
Q1 | – | Sell |
-5,500
| Closed | -$67K | – | 1864 |
|
|
2016
Q4 | $67K | Buy |
+5,500
| New | +$71.2K | 0.01% | 963 |
|
|
2016
Q1 | – | Sell |
-1,855
| Closed | -$42K | – | 1607 |
|
|
2015
Q4 | $42K | Sell |
1,855
-8,108
| -81% | -$160K | 0.01% | 1079 |
|
|
2015
Q3 | $233K | Buy |
+9,963
| New | +$275K | 0.03% | 525 |
|
Prelude Capital Management's XENT Position: Q2 2022 in Review
Prelude Capital Management sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 197,047 shares — an estimated $5.52M sold.
Prelude Capital Management first reported a position in XENT in Q3 2015 and held it in 13 quarters. The position peaked at $5.52M in Q1 2022. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.
- Prelude Capital Management reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
- Prelude Capital Management sold 197,047 Intersect ENT, Inc shares in Q2 2022, an estimated $5.52M.
- Prelude Capital Management first reported a position in Intersect ENT, Inc in Q3 2015 and held it in 13 quarters.
- Prelude Capital Management's Intersect ENT, Inc position peaked at $5.52M in Q1 2022.
- 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.
Based on Prelude Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.